This brand name is authorized in Brazil, United States
The drug AFREZZA contains one active pharmaceutical ingredient (API):
|
1
Insulin (human)
UNII 1Y17CTI5SR - INSULIN HUMAN
|
|
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| AFREZZA Inhalation Powder | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: BR | Câmara de Regulação do Mercado de Medicamentos | Identifier(s): 574519100000407, 574519100000507, 574519100000607, 574519100000707, 574519100000807, 574519100000907 |
| Country: US | FDA, National Drug Code | Identifier(s): 47918-874, 47918-878, 47918-891 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
